Board of Directors

Kirsten Müller-Vahl, MD, Germany, 1st Chairwoman Kirsten Müller-Vahl, MD,
Germany, 1st Chairwoman
In 1990 I graduated as Dr. med. at the Hannover Medical School, Germany. From 1991-1996 I worked as a scientific assistant at the Clinic of Neurology at the Hannover Medical School. From 1997 - 2003 I worked as an assistant professor awarded by a scholarship from the Lower Saxon Government in Germany. In 2003 I qualified as a professor of Experimental Psychiatry. In 2003 I started working as a scientific assistant at the Clinic of Psychiatry, Socialpsychiatry and Psychotherapy at the Hannover Medical School. In 2001 I qualified as a neurologist and in 2006, in addition, I qualified as a psychiatrist. Since 2006 I am working as an Associate Professor of Psychiatry and an assistant medical director at the Clinic of Psychiatry, Socialpsychiatry and Psychotherapy at the Hannover Medical School. In 1994 I started building up a special department for patients suffering from tic disorders and Tourette-syndrome. Since 1996 I am the head of this department. Based on this clinical work, in 1997 I became interested in the clinical effect of cannabinoids in the treatment of movement disorders. Subsequently, I performed several studies investigating the effect of delta-9-tetrahydrocannabinol in the treatment of tics and other psychiatric disorders. In collaboration with the department of human genetics and the clinic of nuclear medicine, I performed studies investigating the role of the central cannabinoid receptor (CNR1) gene and of binding sites of the central cannabinoid receptor (CB1) in the pathology of tic disorders.
Since 1998 I am a member of the advisory board of the German Tourette Association. From 2003 - 2006 I was a member of the International Steering Committee - Tourette Syndrome International Database Consortium (TIC). Since 1999 I am a member of the board of directors of the German Association for Cannabis as Medicine (ACM). In 2000 I was one of the founder members of the International Association of Cannabis as Medicine (IACM). For more details including my list of publications please visit this homepage of the Medical School of Hannover.


Kirsten Müller-Vahl, MD, Germany, 1st Chairwoman Kirsten Müller-Vahl, MD,
Germany, 1st Chairwoman
In 1990 I graduated as Dr. med. at the Hannover Medical School, Germany. From 1991-1996 I worked as a scientific assistant at the Clinic of Neurology at the Hannover Medical School. From 1997 - 2003 I worked as an assistant professor awarded by a scholarship from the Lower Saxon Government in Germany. In 2003 I qualified as a professor of Experimental Psychiatry. In 2003 I started working as a scientific assistant at the Clinic of Psychiatry, Socialpsychiatry and Psychotherapy at the Hannover Medical School. In 2001 I qualified as a neurologist and in 2006, in addition, I qualified as a psychiatrist. Since 2006 I am working as an Associate Professor of Psychiatry and an assistant medical director at the Clinic of Psychiatry, Socialpsychiatry and Psychotherapy at the Hannover Medical School. In 1994 I started building up a special department for patients suffering from tic disorders and Tourette-syndrome. Since 1996 I am the head of this department. Based on this clinical work, in 1997 I became interested in the clinical effect of cannabinoids in the treatment of movement disorders. Subsequently, I performed several studies investigating the effect of delta-9-tetrahydrocannabinol in the treatment of tics and other psychiatric disorders. In collaboration with the department of human genetics and the clinic of nuclear medicine, I performed studies investigating the role of the central cannabinoid receptor (CNR1) gene and of binding sites of the central cannabinoid receptor (CB1) in the pathology of tic disorders.
Since 1998 I am a member of the advisory board of the German Tourette Association. From 2003 - 2006 I was a member of the International Steering Committee - Tourette Syndrome International Database Consortium (TIC). Since 1999 I am a member of the board of directors of the German Association for Cannabis as Medicine (ACM). In 2000 I was one of the founder members of the International Association of Cannabis as Medicine (IACM). For more details including my list of publications please visit my homepage www.mh-hannover.de/mueller-vahl.html


Roger Pertwee, PhD, UK, 2nd Chairman Roger Pertwee, PhD, UK, 2nd Chairman
I am Professor of Neuropharmacology at the University of Aberdeen in Scotland and also Director of Pharmacology for GW Pharmaceuticals, co-chair of the International Union of Pharmacology (IUPHAR) Subcommittee on Cannabinoid Receptors, International Secretary and a past President of the International Cannabinoid Research Society, and co-ordinator of the British Pharmacological Society's Special Interest Group on Cannabinoids. My research group, which has focused since the late 1960's mainly on the pharmacology and therapeutic potential of cannabinoids, contributed to the discovery of endocannabinoids and the endocannabinoid system. It has also played major roles in the development of cannabinoid bioassays, some widely used (e.g. the "ring test" and mouse vas deferens assay), in the discovery of a CB1 receptor allosteric site, and in the discovery/characterization of certain plant cannabinoids and of novel synthetic cannabinoids, eg. the first water-soluble cannabinoid (O-1057), the first CB1-selective agonists (e.g. methanandamide) and a widely-used CB2 receptor antagonist (AM630). My papers on cannabinoid pharmacology are frequently cited (see http://isihighlycited.com/).


Franjo Grotenhermen, MD, Germany, Executive Director Franjo Grotenhermen, MD, Germany, Executive Director
I am a principal of the nova-Institute, Hürth (near Cologne), Germany, and chairman of the German Association for Cannabis as Medicine (ACM). Im working as a medical doctor in private practice and most patients seek a treatment with cannabis or cannabinoids. I have been a key team member to several efforts on cannabis policy in and outside of Germany, including the medical use of cannabis and cannabinoids, the potential impacts of THC residues in hemp foods, and the issue of cannabis and driving. I am editor of "Cannabis and Cannabinoids. Pharmacology, Toxicology and Therapeutic Potential", published in German, English and Spanish, and "Cannabis, Straßenverkehr und Arbeitswelt" [Cannabis, Driving and Workplace] in German, and author of "Hanf als Medizin [Hemp as Medicine], published in several languages including French and Spanish. More.

 

Rudolf Brenneisen, PhD, Switzerland Rudolf Brenneisen, PhD, Switzerland
I am a professor of Pharmaceutical Sciences at the University of Bern and head of the group of Phytopharmacology, Bioanalytics & Pharmacokinetics at the Department of Clinical Research. I am involved in Cannabis research for soon 30 years, first focussing on phytochemistry and analytics, later on pharmaceutics and clinical use. Currently we are focussing on the development and in vitro/in vivo validation of inhalable cannabinoid aerosols. For more details of my CV, lab, research projects, and recent publications see www.phytopharm.dkf.unibe.ch .


Ethan Russo, MD, USA Ethan Russo, MD, USA
Ethan Russo, MD, is a board-certified child and adult neurologist formerly with Montana Neurobehavioral Specialists in Missoula, MT. He is a researcher in migraine, ethnobotany, medicinal plants, cannabis and cannabinoids in pain management, and the therapeutic applications of Schedule I plants and chemicals. He serves in a consultancy position as Senior Medical Advisor to GW Pharmaceuticals Group.
Dr. Russo holds faculty appointments as adjunct associate professor in the Department of Pharmaceutical Sciences of the University of Montana, and clinical associate professor in the Department of Medicine of the University of Washington.
He has published numerous articles in scientific journals and is the author of Handbook of Psychotropic Herbs: A Scientific Analysis of Herbal Preparations for Psychiatric Conditions. He is co-editor with Franjo Grotenhermen of the book, Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential, and author of the novel, The Last Sorcerer: Echoes of the Rainforest, all from Haworth Press.
Dr. Russo was the founding editor of Journal of Cannabis Therapeutics: Studies in Endogenous, Herbal and Synthetic Cannabinoids. He lives in Missoula, MT surrounded by nature, is married to a pediatric nurse practitioner, and has two teenage children.


Daniela Parolaro, PhD, Italy Daniela Parolaro, PhD, Italy


William Notcutt, MD, UK William Notcutt, MD, UK

I qualified in Birmingham, UK in 1970, worked as a Flying Doctor in Lesotho, then specialised in anaesthesia. It was in 1975 whilst working at the University of the West Indies in Kingston, Jamaica that I first came across cannabis being used medicinally in the treatment of alcoholism. I returned to the UK in 1979 and finally I moved to a Consultant post in Gt Yarmouth in 1982.

Although I have remained an anaesthetist, my main interest has been in pain relief. I started up the Palliative Care Service in 1985. I introduced Patient Controlled Analgesia (PCA) for patients for Post-Operative pain.
In the early 1990's I started trying Nabilone for patients with intractable chronic pain with some success. I visited government ministers to discuss the possible of cannabis as a medicine. On the 1/5/2000, we were able to start using purified cannabis medicinal extracts from G W Pharmaceuticals on patients in a clinical trial.

Currently I am the Director of Pain Relief Services, the Lead Clinician for the Back Pain Team and run the cannabis research team. I am also an Honorary Senior Lecturer at the University of East Anglia in Norwich.


Kurt Blaas, MD, Austria Kurt Blaas, MD, Austria
General Practitioner and army doctor in Vienna, Austria
Specialist for the treatment of drug and alcohol abuse
Chairman of CAM-Austria (Arbeitsgemeinschaft Cannabis Als Medizin)

– Area of responsibility
- application of cannabis products in practice
- adjustment and prescription of various legal medicines containing cannabis
- treatment of a wide variety of neurological and psychiatric illnesses
catchment area: nation-wide, several hundred patients

– Public relations work
- diverse lectures
- informational events
- press and TV appearances


Mark Ware, MD, Canada Mark Ware, MD, Canada


Marta Duran, MD, Spain Marta Duran, MD, Spain


Patient Representative

Clare Hodges, UK, Alliance for Cannabis Therapeutics Clare Hodges, UK, Alliance for Cannabis Therapeutics
I graduated from Oxford University in Latin and Greek and then worked as a journalist on newspapers for doctors. From 1981 I worked in television as producer of medical documentaries which involved filming in China, Japan, India, Bangladesh, America, and Israel.
I was diagnosed with Multiple Sclerosis in 1983, but it was 1992 before I started using cannabis to help my condition after I read a medical report from America. With two other patients I set up the Alliance for Cannabis Therapeutics (ACT) in 1992 with the support of the American organisation of the same name. It is an informal association of patients, doctors and politicians.
The ACT initiated the debate about medical use of cannabis in the UK. We kept the debate going by giving interviews and writing articles for the press. We then could exert pressure politically and took two delegations to the Department of Health and Home Office. On the second one in 1997 the ACT asked Geoffrey Guy to join us and we asked the ministers if he could be given a licence to cultivate cannabis for research. Shortly afterwards, GW was founded and is now leading research.
In 1997 the ACT was very involved in the British Medical Association's official report 'The therapeutic uses of cannabis. I was interviewed by a House of Lords Select Committee in 1998 on the subject and have appeared as an expert witness in a trial about illegal use of medical cannabis.
My birth name is Elizabeth Clare Brice. Clare Hodges is a name I adopted to run the ACT to protect my children who were young at the time.